The Food and Drug Administration’s (FDA) decision to authorize the Novavax COVID-19 vaccine for emergency use may be delayed due to the FDA reviewing changes to the company’s manufacturing process.
Novavax told The Epoch Times that the company updated the FDA on changes to its manufacturing process on June 3, days before the advisory committee was scheduled to review its vaccine’s safety and efficacy data.
